GeNeuro SA (GNRO.PA)
EUR 0.08
(6.38%)
EUR 0.08
(6.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -14.31 Million EUR | -12.15% |
| 2022 | -11.77 Million EUR | -76.36% |
| 2021 | -6.78 Million EUR | 6.06% |
| 2020 | -9.1 Million EUR | 19.43% |
| 2019 | -9.56 Million EUR | -118949.99% |
| 2018 | -8.03 Million EUR | -41.42% |
| 2017 | -5.68 Million EUR | 53.43% |
| 2016 | -12.19 Million EUR | -184.08% |
| 2015 | -4.29 Million EUR | -100.19% |
| 2014 | 2.24 Million EUR | 167.91% |
| 2013 | -3.28 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | -7415.10 EUR | 0.0% |
| 2023 FY | - EUR | -19.12% |
| 2023 Q2 | -7.63 Million EUR | 0.0% |
| 2022 Q4 | -6.77 Million EUR | 0.0% |
| 2022 FY | - EUR | -76.36% |
| 2022 Q2 | -5.99 Million EUR | 0.0% |
| 2021 Q4 | -3.3 Million EUR | 0.0% |
| 2021 Q2 | -3.93 Million EUR | 0.0% |
| 2021 FY | - EUR | 6.06% |
| 2020 FY | - EUR | 19.43% |
| 2020 Q4 | -3.91 Million EUR | 0.0% |
| 2020 Q2 | -3.76 Million EUR | 0.0% |
| 2019 FY | - EUR | -118949.99% |
| 2019 Q4 | -4.91 Million EUR | 0.0% |
| 2019 Q2 | -4.64 Million EUR | 0.0% |
| 2018 Q4 | -5643.60 EUR | 0.0% |
| 2018 Q2 | -2390.00 EUR | 0.0% |
| 2018 FY | - EUR | -41.42% |
| 2017 Q4 | 2250.20 EUR | 0.0% |
| 2017 Q2 | -7931.00 EUR | 0.0% |
| 2017 FY | - EUR | 53.43% |
| 2016 Q4 | -6342.10 EUR | 0.0% |
| 2016 FY | - EUR | -184.08% |
| 2016 Q2 | -5855.60 EUR | 0.0% |
| 2015 Q2 | -1551.50 EUR | 0.0% |
| 2015 FY | - EUR | -100.19% |
| 2015 Q4 | -2742.30 EUR | 0.0% |
| 2014 Q3 | 567.45 Thousand EUR | 28714.29% |
| 2014 Q1 | 567.45 Thousand EUR | 0.0% |
| 2014 Q2 | -1983.10 EUR | -100.35% |
| 2014 FY | - EUR | 167.91% |
| 2014 Q4 | 4227.70 EUR | -99.25% |
| 2013 FY | - EUR | 0.0% |
| 2013 Q1 | -835.55 Thousand EUR | 0.0% |
| 2013 Q3 | -835.55 Thousand EUR | 0.0% |
| 2013 Q4 | 567.45 Thousand EUR | 167.91% |
| 2013 Q2 | -835.55 Thousand EUR | 0.0% |
| 2012 Q4 | -835.55 Thousand EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -335.188% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 89.252% |
| Adocia SA | -22.73 Million EUR | 37.015% |
| Aelis Farma SA | -6.34 Million EUR | -125.582% |
| Biophytis S.A. | -13.8 Million EUR | -3.721% |
| Advicenne S.A. | -6.24 Million EUR | -129.303% |
| genOway Société anonyme | 6.35 Million EUR | 325.449% |
| IntegraGen SA | -52.5 Thousand EUR | -27170.251% |
| Medesis Pharma S.A. | -3.84 Million EUR | -272.383% |
| Neovacs S.A. | -8.44 Million EUR | -69.449% |
| NFL Biosciences SA | -4.04 Million EUR | -253.584% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 19840.383% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -398.27% |
| Sensorion SA | -22.31 Million EUR | 35.835% |
| Theranexus Société Anonyme | -7.38 Million EUR | -93.817% |
| TME Pharma N.V. | -5.07 Million EUR | -182.289% |
| Valbiotis SA | -6.95 Million EUR | -105.862% |
| TheraVet SA | -517.33 Thousand EUR | -2667.582% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 24.309% |
| argenx SE | -199.5 Million EUR | 92.823% |
| BioSenic S.A. | -6.79 Million EUR | -110.678% |
| Celyad Oncology SA | -7.76 Million EUR | -84.435% |
| DBV Technologies S.A. | -79.53 Million EUR | 81.997% |
| Galapagos NV | 51.03 Million EUR | 128.054% |
| Genfit S.A. | -28.05 Million EUR | 48.958% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 4.421% |
| Innate Pharma S.A. | -7.57 Million EUR | -88.938% |
| Inventiva S.A. | -101.84 Million EUR | 85.942% |
| MaaT Pharma SA | -19.74 Million EUR | 27.469% |
| MedinCell S.A. | -20.04 Million EUR | 28.576% |
| Nanobiotix S.A. | -34.01 Million EUR | 57.913% |
| Onward Medical N.V. | -35.23 Million EUR | 59.364% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -222.954% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 38.461% |
| Oxurion NV | -16.72 Million EUR | 14.414% |
| Pharming Group N.V. | 4.98 Million EUR | 387.448% |
| Poxel S.A. | -12.17 Million EUR | -17.561% |
| GenSight Biologics S.A. | -21.73 Million EUR | 34.111% |
| Transgene SA | -27.02 Million EUR | 47.019% |
| Financière de Tubize SA | 184.57 Thousand EUR | 7857.286% |
| UCB SA | 1.26 Billion EUR | 101.128% |
| Valneva SE | -64.51 Million EUR | 77.808% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 49.502% |